Connect MM: The Multiple Myeloma Disease Registry
Rafat Abonour, MD
Primary Investigator
Brief description of study
What is the purpose of this study?
This research study is being done to learn more about multiple myeloma and its treatments. The researchers also want to better understand how multiple myeloma impacts the life of people living with multiple myeloma.
The primary objective of the Connect® MM Registry is to:
• Describe practice patterns of common first-line treatment regimens and subsequent therapeutic strategies as well as diagnostic patterns in patients newly diagnosed with MM in the community and academic setting
• Describe and characterize the occurrence of second primary malignancies
The secondary objectives of the registry are to:
• Provide insight into treatment regimens and therapy sequence in clinical practice as they relate to clinical outcomes (response, overall survival, progression-free survival) in patients newly diagnosed with MM
• Describe any differences in effectiveness associated with treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects in patients newly diagnosed with symptomatic MM
• Describe the health-related quality of life (HRQoL) of patients with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes
Detailed description of study
What will happen during the study?
There is no planned investigational agent, prescribed treatment regimen, or mandated intervention in this study. The treating physician will determine the enrolled patient’s therapy for newly diagnosed MM according to his or her clinical judgment. Enrolled patients will receive treatment and evaluations for MM according to the standard of care and clinical practice at each study site. All treatments that patients receive for multiple myeloma will be recorded, including initial treatment and any subsequent therapy. Treatment outcomes, including response rates as measured by the treating physician, evidence of progression, and survival status, will be collected quarterly. Subjects will be asked to complete health-related quality of life questionnaires at baseline, and then every three months for their duration of participation in the study. The questionnaire may also be completed at home.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple Myeloma, Cancer
-
Age: 18 years - 100 years
-
Gender: All
Inclusion criteria:
• Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
• Age ≥18 years
• Willing and able to provide signed informed consent
• Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
